Hereditary Liver Diseases
Hereditary liver diseases, driven by monogenic mutations and multiorgan pathologies, require precise therapeutic strategies addressing both molecular defects and clinical manifestations. Protheragen develops targeted gene correction and liver-directed delivery platforms to overcome these challenges through collaborative research and translational innovation.
Overview
Clinical Challenges
- Diagnostic Complexity
Delayed and inaccurate diagnoses persist as critical barriers, exemplified by 5-7 year diagnostic delays in Wilson's disease and 30% misdiagnosis rates in alpha-1 antitrypsin deficiency. These delays accelerate irreversible organ damage and complicate therapeutic interventions.
- Therapeutic Limitations
Existing treatments-copper chelation, protein replacement, and invasive surgeries-focus on symptom mitigation rather than causal correction. Side effects, variable efficacy, and lack of disease-modifying effects underscore the limitations of current paradigms.
- Monitoring Difficulties
The absence of validated progression biomarkers and heterogeneous phenotypic expression-even among patients with identical mutations-impedes personalized management. This variability complicates treatment optimization and timely intervention adjustments.
Fig1. Framework for considering and incorporating genetic testing into the evaluation and management of patients with liver disease. (Konkwo, et al., 2024)Genetic Characteristics of Hereditary Liver Diseases
The genetic heterogeneity of hereditary liver diseases directly informs therapeutic design and patient stratification:
| Mutation Spectra | Inheritance Patterns | Genotype-Phenotype Relationships |
|---|---|---|
|
|
|
Fig2. Major molecular proteins involved in genetic cholestasis. (Karlsen, et al., 2015)Advancements in Treatment
The treatment landscape is rapidly evolving through technological convergence, bridging molecular insights with clinical translation:
- Emerging Therapeutic Modalities
CRISPR-based gene editing enables precise correction of mutations (e.g., ATP7B in Wilson's disease), while mRNA therapies provide transient protein replacement for disorders like alpha-1 antitrypsin deficiency. Small molecule chaperones offer a complementary strategy to stabilize misfolded proteins, exemplified by SERPINA1 variant rescue in preclinical models.
- Clinical Translation Progress
Over 20 gene therapies and 4 RNAi candidates (e.g., ALN-AAT02) are advancing through trials for metabolic liver diseases. Phase II/III studies demonstrate improved hepatic Z-AAT polymer clearance in AATD, highlighting modality-specific efficacy.
- Delivery System Innovations
Engineered AAV capsids achieve >80% hepatocyte transduction efficiency in non-human primates, while lipid nanoparticles enable CRISPR ribonucleoprotein delivery with reduced immunogenicity. Patient-derived organoids now guide individualized vector dosing and regimen optimization.
Our Services
Genetic Analysis & Custom Disease Models
We identify and validate disease-causing mutations through NGS panels covering 57+ genes (e.g., ATP7B, SERPINA1), and recreate patient-specific pathology using iPSC-derived hepatocytes, 3D organoids, and isogenic controls.
Mutation-Tailored Gene Editing
Using CRISPR/Cas9 and base/prime editing, we correct point mutations or large deletions. Our optimized HDR/NHEJ protocols achieve >80% editing efficiency in primary hepatocytes, validated through functional assays like copper flux measurements.
Liver-Focused Delivery Solutions
We engineer AAV capsids with 90%+ hepatocyte targeting in primates and design GalNAc-conjugated siRNAs for RNA therapy delivery. Services include promoter optimization for sustained gene expression and spatial mapping of therapeutic biodistribution.
Preclinical Efficacy & Safety Validation
We validate therapeutic candidates using clinical-stage biomarkers in preclinical models, including Z-AAT polymer clearance in patient-derived organoids, serum copper level normalization in Wilson's disease mice, and bile acid transport restoration in PFIC cholangiocyte models. Safety studies rigorously assess off-target editing (WGS/CIRCLE-seq), immunogenicity (AAV NAbs in NHPs), and hepatocyte engraftment durability.
Multimodal Therapeutic Development
Beyond gene editing, we develop RNA splice modulators to bypass SERPINA1 mutations, engineer stabilized protein variants for AATD, and optimize small molecule chaperones. Cell therapies include CRISPR-edited hepatocytes with validated repopulation capacity in preclinical models.
Through our customized service for hereditary liver diseases, you can accelerate the treatment and research process of rare hereditary liver diseases, and improve the accuracy and effectiveness of the treatment. If you are interested in our services or wish to know more information, please feel free to contact us at any time.
FAQs?
-
Q: What types of genetic liver diseases do you specialize in?
A: Our research focuses on genetic liver disorders, including Wilson's disease and alpha-1 antitrypsin deficiency, which stem from mutations affecting hepatic function and metabolic regulation.
-
Q: What is the average duration for a gene correction study?
A: Gene correction projects typically require 3–6 months, depending on experimental scope, model complexity, and validation requirements. Timelines encompass design, execution, and functional validation phases.
-
Q: Do you provide AAV vector development support?
A: Yes, we offer end-to-end AAV vector development services, including capsid optimization, scalable production, and in vivo delivery efficiency assessments tailored for liver-targeted therapies.
-
Q: Which gene-editing platforms do you utilize?
A: Our workflows employ CRISPR/Cas9 systems for precise genome editing and AAV vectors for efficient gene delivery, ensuring robust validation of therapeutic candidates in physiologically relevant models.
References
- Karlsen TH.; et al. Genetics of liver disease: From pathophysiology to clinical practice. J Hepatol. 2015;62(1 Suppl):S6-S14.
- Konkwo C.; et al. Genetics of liver disease in adults. Hepatol Commun. 2024;8(4):e0408.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.